New Global Study Will Assess Lower Booster Doses As Vaccine-Sparing Measure
Executive Summary
In the run-up to a major pandemic preparedness summit in London next month, CEPI has announced a new trial aimed at broadening access to vaccines in lower-income countries and has welcomed fresh funding for its plan to cut vaccine development times to 100 days.
You may also be interested in...
How AI Can Help Reduce Vaccine R&D From A Year To ‘A Matter Of Weeks’
From rapidly identifying antigenic targets to automating clinical trials, AI has an important role to play in cutting vaccine development time down to 100 days, says Melanie Saville, executive director of R&D at CEPI.
Global Summit Hears Pledges To Cut Pandemic Vaccine Development Times
Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.
EU Gets Go-Ahead To Negotiate Global Pandemic Treaty
The process of drafting an international agreement on pandemic preparedness and response is picking up speed, although one NGO has warned that this must not distract from more immediate priorities such as technology transfer for producing COVID-19 medical products.